merged_340b-apexus-drugs-middleman.txt
<other>Processing question 1: The article states Apexus is a subsidiary of Vizient (a hospital-owned business), was established as a nonprofit in 2007 but became for-profit in 2014, and a 2022 memo projected $227 million revenue with profit margins above 80%. This matches all criteria.</other>
<question_number>1</question_number>
<answer>Apexus</answer>
<other>Processing question 2: Marsha Simon, who helped draft the legislation, is quoted saying "They've got a license to hunt" about Apexus specifically.</other>
<question_number>2</question_number>
<answer>Apexus</answer>
<other>Processing question 3: The article describes Apexus' "purchasing optimization team" analyzing drug-buying patterns, with a 2022 PowerPoint showing revenue-based bonuses. Government officials directed it to focus solely on administration.</other>
<question_number>3</question_number>
<answer>Apexus</answer>
<other>Processing question 4: Virginia King's case details the $22,700 bill from Christus St. Vincent (340B-participating) versus $8,000 at a non-participating clinic for the same injection.</other>
<question_number>4</question_number>
<answer>Virginia King</answer>
<other>Processing question 5: New York's Medicaid director stated the cost of the federal program (340B) increased by more than 200% over three years, leading to 2023 changes.</other>
<question_number>5</question_number>
<answer>340B</answer>
<other>Processing question 6: Apexus sells a $750 certification course and employees advised hospitals to review records up to 36 months back for patient eligibility.</other>
<question_number>6</question_number>
<answer>Apexus</answer>
<other>Processing question 7: Krista Pedley reprimanded Apexus for acting "more like a sales-driven business than a program administrator" during the Skype meeting.</other>
<question_number>7</question_number>
<answer>acting like a sales-driven business</answer>
<other>Processing question 8: The North Carolina report found 340B-participating hospitals billed 85% more for cancer drugs, with the melanoma drug example ($8,000 cost vs $21,512 bill).</other>
<question_number>8</question_number>
<answer>North Carolina</answer>
<other>Processing question 9: Acentrus, which helped hospitals get deeper discounts on specialty drugs, was sold last year according to the article.</other>
<question_number>9</question_number>
<answer>Acentrus</answer>
<other>Processing question 10: Apexus, based in Irving, Texas, charges 3% on generic drugs and fees on non-340B purchases; Baxter attempted to bypass it in 2021.</other>
<question_number>10</question_number>
<answer>Apexus</answer>